NIOX® Heritage
At NIOX® we are proud to be the pioneers behind commercial FeNO testing!
1989
The importance of nitric oxide was established in the late 1980s when scientists discovered this tiny molecule had signalling properties. Their work would eventually lead to a Nobel Prize.
1991
Researchers at the Karolinska Institute in Sweden identified the presence of NO in human lungs.
1992
Science magazine names NO its Molecule of the Year, citing the versatility and importance of the gas.
1993
Scientists demonstrate that asthma patients exhale increased levels of NO.
1994
A reduction in NO after steroid therapy in asthma patients is uncovered for the first time.
1998
The Nobel Prize in Physiology or Medicine was awarded for discoveries concerning NO as a signalling molecule.
NO Discoveries:
1998
The scientists that discovered FeNO and it's link to asthma start a company called Aerocrine AB in 1997 and launched the first FeNO device for commercial use in 1998.
2000
NIOX FLEX® receives approval as a medical device in Europe, enhancing testing capabilities for healthcare professionals in the diagnosis and management of asthma.
2005
The introduction of NIOX MINO® offers users a hand-held, portable FeNO analyser for the first time.
2005
The European Respiratory Society (ERS) and the American Thoracic Society (ATS) publish a joint recommendation on the standardisation of FeNO and nasal NO (nNO) measurement techniques.
NIOX® Founded:
2011
The ATS guidelines are released with individual cut-off points for asthma diagnosis and management with FeNO.
2013
NIOX® releases the new NIOX VERO®, designed on user feedback, NIOX VERO® becomes the flagship FeNO testing device.
2017
NIOX VERO® introduces the nasal application for the measurement of nNO, bringing new options for the diagnosis of primary ciliary dyskinesia (PCD).
2018
For the first time, GINA recognises the importance of FeNO testing to help assess the Type 2 phenotype and select the right biologic in severe asthma patients.
2019
NIOX® wins Small Diagnostic Manufacturer of the Year 2019 from the Association for Respiratory Technology and Physiology (ARTP).
2020
NIOX VERO® wins MedTech Award for the Most Advanced Asthma Solution 2020
2021
Over 40 million FeNO tests have been performed with NIOX® technology, a major milestone.
2021
NIOX® takes home Global Leaders in FeNO Testing 2021 at the Global Health and Pharma Awards.
2021
NIOX VERO® is named Most Innovative Asthma Management Technology 2021 at the Global Health and Pharma Awards.
2022
NIOX® is awarded Best FeNO Testing Provider at the M&A Today Global Awards 2022.
2022
NIOX® wins Leaders in FeNO Testing Technology Development at the AI Research & Development Awards 2022.
2023
At NIOX® we are dedicated to transforming asthma care. That’s why we are excited to announce 50 million FeNO tests have now been performed with NIOX® technology!
FeNO by NIOX®:
Celebrating
In 2023 we are proud to celebrate 25 years of NIOX® technology. From a chance discovery to millions of tests peformed, learn more about the full NIOX® story here.
25 Years of NIOX®:
2024
Another key milestone reached! We are delighted to share that 55 million FeNO tests have been performed with NIOX® Technology.
The future of FeNO:
Request a quote for a device today with our simple and easy to use quotation tool. Used by thousands of healthcare professionals, NIOX® is the global device of choice for FeNO testing.
Request a Quote
Discover why you should choose NIOX® as your FeNO partner.
Why NIOX®At NIOX® we are passionate about providing excellent support and training.